In vitro cell binding tests to evaluate the targeting of PSMA was performed using autoradiography, flow cytometry, and internalization assays on different prostate cancer cell lines and patient-derived xenografts (PDXs). This evidence concerns the gene FOLH1 and prostate cancer.